The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LTRN | +28.32% | -73.44% | -23.27% | -73% |
| S&P | +19.89% | +109.18% | +15.89% | +128% |
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 90.3% |
| Market Cap | $34.08M | -32.2% |
| Market Cap / Employee | $1.42M | 0.0% |
| Employees | 24 | 14.3% |
| Net Income | -$4.33M | 12.7% |
| EBITDA | -$4.65M | 13.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.06M | -53.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.01M | -75.3% |
| Short Term Debt | $0.13M | -19.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.63% | -31.8% |
| Return On Invested Capital | -41.87% | 31.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.94M | 24.2% |
| Operating Free Cash Flow | -$3.94M | 24.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.28 | 1.29 | 1.80 | 2.03 | 44.60% |
| Price to Tangible Book Value | 1.28 | 1.29 | 1.80 | 2.03 | 44.60% |
| Enterprise Value to EBITDA | -2.29 | -1.82 | -3.91 | -3.94 | 22.91% |
| Return on Equity | -53.0% | -66.9% | -75.7% | -88.6% | 97.65% |
| Total Debt | $0.29M | $0.24M | $0.19M | $0.15M | -33.68% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
